Scancell Share Discussion Threads

[ruckrover] 14/1/2025 09:44

"please explain which one has failed and why"Neither has failed. Early combination data in small numbers looks promising. I am hoping for synergy and think it is highly likely.As of now, it is not clinically proven.

[inanaco] 14/1/2025 09:42

its like betting on a horse knowing the winner

i won big first time around with the No risk posts

and of course that still applies

No risk in scancell at all .... Mcap is covered by Scib1

i really do not know what your problem is ............

[inanaco] 14/1/2025 09:38

clinically proven does not buy you shares at 9.7p ...

mechanically it has to work .............

otherwise

which one has failed


Modi1 failed to get an immune response as a mono therapy

Ctl-4

opdivo

please explain which one has failed and why

[ruckrover] 14/1/2025 09:35

Inan, "ruck read it ... its in there"OK, got it for reason the search couldn't find synergised even though it's there.The key word there is "tenet". So they believe and hope it will work but this as yet is not clinically proven.

[inanaco] 14/1/2025 09:34

i am now saying to you Modi1 as a combo with double CPI is a major game changer


scancell describing this a Highly synergistic with vaccines

rather than treating yourself as a failure ....

look at it as sticking the course as a positive because you never know when Big Pharma jumps in ...

2tyke cannot predict that .... and never will

[inanaco] 14/1/2025 09:31

Scib1 and Synergy gave you the "no Risk Posts"

mechanically its has to work

It did ...................

1.7m shares

[inanaco] 14/1/2025 09:23

ruck read it ... its in there

I keep telling you ... 2015

which one has failed

Scib1

or

Keytruda


you will have synergy


same applies to Modi1

Modi1 works you will have synergy


but you don't believe it

[ruckrover] 14/1/2025 09:19

Is that in the TD report?

[inanaco] 14/1/2025 09:12

and a Point that you should take notice of Ruck

As with the SCOPE trial with ImmunoBody, the tenet is that doublet CPI therapy is highly synergised when coupled with targeted vaccines. An arm exploring Modi-1 in combination with CPIs in advanced renal cell carcinoma (RCC) is underway.


""highly synergised"" when coupled with targeted vaccines


like i said Ctl-4 is a game changer for CD4 T cell activation

Pd-1 is secondary treatment after activation a continuing treatment protecting the t cells

what Ctl-4 is doing is all at the start of treatment it gives activation a very big kick indeed

[ruckrover] 14/1/2025 09:11

But, you would think logically, if it is a big revision upward the the forecast would be higher

[ruckrover] 14/1/2025 09:11

Inan, The difficulty is that this new report doesn't have the valuation table that previous reports did so it makes a detailed comparison impossible.

[ruckrover] 14/1/2025 09:09

City Finance were the sellers that caused the drop to 3.5p

[inanaco] 14/1/2025 08:51

Ruck ... you are the Data Scientist

you can answer your own questions

try talking to yourself

consult a mirror

[inanaco] 14/1/2025 08:49

Exactly Roger, those that can see the inherent value do not fret

you only have to look at the posters that do

Ruck
Nigel

they seem to think the Stock Market is the bell weather price it isn't

Calculus is testament to that and indeed i can't remember which house caused 3.5p but that sell off did happen and those that bought benefited

considering the data we do have its a pretty good guide that Scancell will progress further

its a buying opportunity ....

[ruckrover] 14/1/2025 08:45

"now clearly with the revised numbers of $3.8 billion based on Iscib1"Not sure about the clearly bit. Does the $3.8 billion cover SCIB1 and iSCIB1? What were the previous numbers?If this is a significant increase, how come the estimate has gone DOWN from 33p to 32p. Dilution would explain it but the increased revenue should more than compensate.

[nigelpm] 14/1/2025 08:44

Agreed roger. Think that's a perfect summation of my position also. The reward will be huge IF any of these products get close to market within the next couple of years. There will likely be further dilution unless the progress is rapid.

[rogerbridge] 14/1/2025 08:40

I can not do anything about the share price, so I have accepted that nothing will happen until we have data or a deal/s.
I do believe the share price is very undervalued but no amount of discussion on this thread will make any difference.
I have made my investment decision and will just wait for action.
Until then, I am not concerned with the day to day share price and will chill out.
With the market in its current state, there is enough to be concerned with, elsewhere.
GLA.

[2tyke] 14/1/2025 08:38

SP's have only 2 parameters...price and time.
Everything else is noise.
Especially from inane.
Human 'notions' and dreams of future 'value' don't figure with stock prices.
All about intellectual honesty ..

[inanaco] 14/1/2025 08:34

now clearly with the revised numbers of $3.8 billion based on Iscib1

you can see how 2 or 3% or what ever it is, change in efficacy by trialing the two guns could be very beneficial

[inanaco] 14/1/2025 08:31

you missed the point of the post Ruck yet again ....

its the £20m that puts Scancell in control ... not the market Ie cap in hand

and considering all the market turbulence because of the Politics

Scancell played the market perfectly by raising early

this is why i post on the politics as well as Scancell ..

as Scancell have told you the anticipated burn rate why are you asking me ?

i thought you was the "Data Scientist"

[ruckrover] 14/1/2025 08:27

"Poor Nigel knocked of his perch by a ?20m cash balance"Don't forget it will only show as a cash balance until it is spent.Do you know what the current cash burn is?

[inanaco] 14/1/2025 08:25

the market has no firm control on Scancell until 2026 when funding becomes an issue again

Poor Nigel knocked of his perch by a £20m cash balance

[inanaco] 14/1/2025 08:21

as a footnote ... Big Pharma will decide the share price not the market, the market can only anticipate what Big Pharma will do

based on the science readouts

still chin Up ... and work the share price down

I suggest try and explain the ORR as an anomaly that will confuse them and hopefully Nigel Big Pharma will take your advice on penny valuations

So GenMab must be another anomaly ... they clearly don't know what they are doing and ignored your advice

[ruckrover] 14/1/2025 08:19

Nigel, Let me try and help you out here. Do you know how much SCIB1/iSCIB1+ and MODI would be worth IF the trials are successful and they make it to market?